- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07299019
Eine Studie zu Orelabrutinib bei Patienten mit sekundär progredienter Multipler Sklerose
Eine Phase-3-, randomisierte, doppelblinde Studie zur Wirksamkeit und Sicherheit von Orelabrutinib im Vergleich zu Placebo bei Patienten mit nicht-aktiver sekundär progredienter Multipler Sklerose
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS. Patients will be treated for approximately 24 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with naSPMS. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.
The study consists of the following periods:
- Screening Period: Up to 4 weeks.
- Treatment Period: The duration of treatment will vary for individual participants ranging from approximately 24 to 60 months, depending on the time of recruitment. A month is defined as a period of 28 days by convention.
- Double-blinded (DB) Treatment: All eligible participants will be randomized at 2:1 ratio to accept orelabrutinib QD or placebo during the DB treatment period. The study will be unblinded when all participants in the DB period have reached a minimum treatment duration of 12 months at the time of primary analysis timing cutoff.
- Open-label (OL) Treatment: Participants with 24-week CDP as assessed by EDSS are eligible for 2-year open-label orelabrutinib treatment.
- Safety Follow-Up Period: It will last 4 weeks. The safety follow-up period will begin when the participants discontinue from the treatment before the end of the trial for any reasons or complete the trial but do not enter the long-term safety study (LTS) (see below).
All active study participants will have a final end of study (EOS) visit within 4 weeks of the study end date. Participants who are receiving IMP in DB or OL but do not consent to or are not eligible for enrollment in the LTS study, must return for a final safety follow-up visit 4 weeks later. For participants who intend and are eligible to join the LTS, open-label treatment with orelabrutinib will continue and no safety follow-up will occur.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
- Name: Patient and Medical Information
- Telefonnummer: 833-269-4696
- E-Mail: clinicaltrialsinfo@zenasbio.com
Studieren Sie die Kontaktsicherung
- Name: Patient and Medical Information
- Telefonnummer: 833-269-4696
- E-Mail: clinialtrialsinfo@zenasbio.com
Studienorte
-
-
New South Wales
-
Kogarah, New South Wales, Australien, 2217
- Rekrutierung
- Southern Neurology Suite 2
-
-
-
-
-
Sovet, Belgien, 1408
- Rekrutierung
- DCC Neoclinic - Sofia
-
-
Limburg
-
Overpelt, Limburg, Belgien, 3900
- Rekrutierung
- MS-Netwerk Limburg - Revalidatie
-
-
-
-
-
Pleven, Bulgarien, 5800
- Rekrutierung
- Avis Medica Hospital Pleven
-
-
Plovdiv
-
Plovdiv, Plovdiv, Bulgarien, 4000
- Rekrutierung
- Medical Center Nevrocentrum
-
-
Sofia
-
Sofia, Sofia, Bulgarien, 1680
- Rekrutierung
- Diagnostic and Consultative Center Convex
-
Sofia, Sofia, Bulgarien, 1510
- Rekrutierung
- Medical Center Hera EOOD
-
-
Tarnovo
-
Veliko Tarnovo, Tarnovo, Bulgarien, 5000
- Rekrutierung
- Medical Center Medica Plus OOD
-
-
-
-
Hesse
-
Bad Homburg, Hesse, Deutschland, 61348
- Rekrutierung
- Zentrum fur klinische Forschung Dr.Scholl GmbH
-
-
-
-
Harju
-
Tallinn, Harju, Estland, 10617
- Rekrutierung
- Astra clinic (Clinic4U)
-
-
-
-
Brest
-
Pordic, Brest, Frankreich, 29609
- Rekrutierung
- CHU Brest Hospital Cavale
-
-
Gard
-
Nîmes, Gard, Frankreich, 30029
- Rekrutierung
- Centre Hospitalier Universitaire de Nimes (CHU) - Hopital Universitaire Caremeau
-
-
Yveline
-
Poissy, Yveline, Frankreich, 78300
- Rekrutierung
- Centre Hospitalier Intercommunal (Chi) Poissy-Saint-Germain-En-Laye - Site De Poissy
-
-
-
-
-
Tbilisi, Georgia, 0114
- Rekrutierung
- LTD Pineo Medical Ecosystem
-
Tbilisi, Georgia, 0186
- Rekrutierung
- Raymann, LLC
-
Tbilisi, Georgia, 0159
- Rekrutierung
- NNLE Jo Ann University Hospital
-
Tbilisi, Georgia, 0186
- Rekrutierung
- Caucasus Medical Center Ltd
-
-
K'alak'i T'bilisi
-
Tbilisi, K'alak'i T'bilisi, Georgia, 0114
- Rekrutierung
- JSC Curatio
-
-
Saburtalo
-
Tbilisi, Saburtalo, Georgia, 0160
- Rekrutierung
- MD Georgia Staff Physician MediClub Georgia
-
-
-
-
Athens
-
Cholargós, Athens, Griechenland, 15562
- Rekrutierung
- Metropolitan General Hospital
-
-
Attica
-
Athens, Attica, Griechenland, 11526
- Rekrutierung
- Errikos Dunant Hospital
-
-
-
-
Chieti
-
Chieti, Chieti, Italien, 66100
- Rekrutierung
- University G. D'Annunzio of Chieti-Pescara
-
-
Isernia/Molise
-
Pozzilli, Isernia/Molise, Italien, 86077
- Rekrutierung
- IRCCS Istituto Neurologico Mediterraneo Neuromed
-
-
-
-
-
Zagreb, Kroatien, 10 000
- Rekrutierung
- Klinicki Bolnicki Centar Zagreb-Rebro
-
-
-
-
Kauno
-
Kaunas, Kauno, Litauen, 50161
- Rekrutierung
- Hospital of Lithuanian University of Health Sciences
-
-
-
-
-
Lublin, Polen, 20-064
- Rekrutierung
- Galen Clinic
-
Plewiska, Polen, 62-064
- Rekrutierung
- Neurologiczny Niepubliczny ZOZ Centrum Leczenia SM Osrodek Badan Klinicznych im. dr n. med. Hanki Hertmanowskiej
-
Poznan, Polen, 15-540
- Rekrutierung
- Prywatna Lecznica Certus Sp. z o.o.
-
Szczecin, Polen, 70-111
- Rekrutierung
- EUROMEDIS Osrodek Badan Klinicznych
-
Żory, Polen, 44-240
- Rekrutierung
- Centrum Medyczne ProNeuro Żory
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polen, 85-605
- Rekrutierung
- Centrum Medyczne INTERCOR Sp. z o.o.
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, Polen, 20-601
- Rekrutierung
- Malva Trials
-
Lublin, Lublin Voivodeship, Polen, 20-064
- Rekrutierung
- Instytut Naukowo-Badawczy w Lublinie Sp. z o.o.
-
Lublin, Lublin Voivodeship, Polen, 20-064
- Rekrutierung
- NZOZ Neuromed M. i M. Nastaj Sp.P
-
-
Lubusz Voivodeship
-
Nowa Sól, Lubusz Voivodeship, Polen, 67-100
- Rekrutierung
- Twoja Przychodnia Centrum Medyczne Nowa Sól
-
-
Mazovian
-
Warsaw, Mazovian, Polen, 02-172
- Rekrutierung
- MTZ Clinical Researcz Powered by pratia
-
-
Rzeszów
-
Rzeszów, Rzeszów, Polen, 35-323
- Rekrutierung
- Nmedis sp. z o.o.
-
-
Silesian Voivodeship
-
Katowice, Silesian Voivodeship, Polen, 40-081
- Rekrutierung
- Centrum Medyczne Pratia Katowice
-
Katowice, Silesian Voivodeship, Polen, 40-571
- Rekrutierung
- MA-LEK Clinical Sp. z o.o.
-
Katowice, Silesian Voivodeship, Polen, 40-584
- Rekrutierung
- NZOZ Novo Med
-
-
Upper Silesia
-
Katowice, Upper Silesia, Polen, 40-686
- Rekrutierung
- Neuro Medic Clinic
-
-
Wielkopolska
-
Poznan, Wielkopolska, Polen, 61-853
- Rekrutierung
- Nzoz Neuro-Kard Ilkowski I Partnerzy Spolka Partnerska Lekarzy
-
Poznan, Wielkopolska, Polen, 60-324
- Rekrutierung
- Twoja Przychodnia PCM
-
-
Łódź Voivodeship
-
Lodz, Łódź Voivodeship, Polen, 91-743
- Rekrutierung
- PRO SALUS Sp. z o.o. sp.k.
-
Lodz, Łódź Voivodeship, Polen, 90-324
- Rekrutierung
- Centrum Neurologii Krzysztof Selmaj
-
-
-
-
-
Guaynabo, Puerto Rico, 00969
- Rekrutierung
- Caribbean Center for Clinical Research
-
-
-
-
Constanța County
-
Constanța, Constanța County, Rumänien, 900123
- Rekrutierung
- Spital Clinic CF Constanta
-
-
Suceava
-
Radauti, Suceava, Rumänien, 725400
- Rekrutierung
- Spitalul Municipal Sf. Doctori Cosma si Damian Radauti
-
-
-
-
-
Kragujevac, Serbien, 34000
- Rekrutierung
- University Clinical Centre of Kragujevac
-
Niš, Serbien, 18000
- Rekrutierung
- Clinic of Neurology - Clinical Center Nis
-
-
Belgrade
-
Belgrade, Belgrade, Serbien, 11000
- Rekrutierung
- University Clinical Centre of Serbia
-
-
-
-
A Coruña
-
A Coruña, A Coruña, Spanien, 15006
- Rekrutierung
- Complejo Hospitalario Universitario A Coruña
-
-
Galicia
-
Vigo, Galicia, Spanien, 36312
- Rekrutierung
- Hospital Alvaro Cunqueiro
-
-
Madrid
-
Madrid, Madrid, Spanien, 28007
- Rekrutierung
- Hospital Gregorio Marañon
-
Majadahonda, Madrid, Spanien, 28222
- Rekrutierung
- Hospital Universitario Puerta de Hierro de Majadahonda
-
-
Málaga
-
Málaga, Málaga, Spanien, 29016
- Rekrutierung
- Vithas Hospital Parque San Antonio
-
-
Seville
-
Castilleja de la Cuesta, Seville, Spanien, 41950
- Rekrutierung
- Hospital Vithas Nisa Sevilla
-
-
-
-
-
Choceň, Tschechien, 56501
- Rekrutierung
- NEUROHK, s.r.o.
-
Jihlava, Tschechien, 58601
- Rekrutierung
- Regional Hospital Jihlava
-
-
-
-
-
Ivano-Frankivsk, Ukraine, 76943
- Rekrutierung
- Neuro Global
-
Lviv, Ukraine, 79010
- Rekrutierung
- Lviv National Medical University named after Danylo Galytskiy
-
Vinnytsia, Ukraine, 21009
- Rekrutierung
- Medical Clinical Investigational Center of Medical Center LLC Health Clinic
-
-
Chernivtsi Oblast
-
Chernivtsi, Chernivtsi Oblast, Ukraine, 58023
- Rekrutierung
- Regional Municipal Non-commercial Enterprise Chernivtsi Emergency Medical Hospital
-
-
Ivano-Frankivs'k Oblast
-
Ivano-Frankivsk, Ivano-Frankivs'k Oblast, Ukraine, 76018
- Rekrutierung
- CNE City Clinical Hospital #1 of Ivano-Frankivsk council
-
-
Lviv Oblast
-
Lviv, Lviv Oblast, Ukraine, 79000
- Rekrutierung
- Limited Liability Company Medical Center Neuroclinic
-
Lviv, Lviv Oblast, Ukraine, 79029
- Rekrutierung
- Limited Liability Company "Neurofocus"
-
-
-
-
-
Budapest, Ungarn, 1145
- Rekrutierung
- National Institute of Clinical Neurosciences
-
Tatabánya, Ungarn, 2800
- Rekrutierung
- Komarom-Esztergom Varmegyei Szent Borbala Korhaz
-
-
Komarom-Esztergom Vamegye
-
Esztergom, Komarom-Esztergom Vamegye, Ungarn, 2500
- Rekrutierung
- Valeomed Kft.
-
-
-
-
Arizona
-
Phoenix, Arizona, Vereinigte Staaten, 85032
- Rekrutierung
- Arizona Neuroscience Research, LLC
-
Scottsdale, Arizona, Vereinigte Staaten, 85253
- Rekrutierung
- Perseverance Research Center, LLC (PRC)
-
-
California
-
Fullerton, California, Vereinigte Staaten, 92835
- Rekrutierung
- Fullerton Neurology and Headache Center
-
Torrance, California, Vereinigte Staaten, 90502-2006
- Rekrutierung
- Harbor-UCLA Medical Center - The Lundquist Institute (Los Angeles Biomedical Research Institute (LA BioMed))
-
West Hollywood, California, Vereinigte Staaten, 90048
- Rekrutierung
- Regina Berkovich MD, PhD Inc
-
-
Florida
-
Boca Raton, Florida, Vereinigte Staaten, 33487
- Rekrutierung
- SFM Clinical Research, LLC
-
Bradenton, Florida, Vereinigte Staaten, 34209
- Rekrutierung
- Nova Clinical Research, LLC
-
Clearwater, Florida, Vereinigte Staaten, 33761
- Rekrutierung
- MS and Neuromuscular Center of Excellence
-
Maitland, Florida, Vereinigte Staaten, 32751
- Rekrutierung
- Neurology Associates
-
Naples, Florida, Vereinigte Staaten, 34105
- Rekrutierung
- Aqualane Clinical Research
-
Tampa, Florida, Vereinigte Staaten, 33612
- Rekrutierung
- University of South Florida Department of Neurology - MS Division
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46256
- Rekrutierung
- Josephson Wallack Munshower Neurology, Pc Suite 225
-
-
Kansas
-
Kansas City, Kansas, Vereinigte Staaten, 66160
- Rekrutierung
- University of Kansas Medical Center
-
Roeland Park, Kansas, Vereinigte Staaten, 66205
- Rekrutierung
- KC Research Center, PA Neurology Research Dept
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02131
- Zurückgezogen
- Boston Clinical Trials
-
Worcester, Massachusetts, Vereinigte Staaten, 01655
- Rekrutierung
- University of Massachusetts Memorial Medical Center
-
-
Michigan
-
Rochester Hills, Michigan, Vereinigte Staaten, 48307
- Rekrutierung
- Profound Research LLC at Oakland Neurology Center
-
-
Missouri
-
St Louis, Missouri, Vereinigte Staaten, 63110
- Rekrutierung
- Washington University School of Medicine
-
-
New Mexico
-
Albuquerque, New Mexico, Vereinigte Staaten, 87131
- Rekrutierung
- University Of New Mexico School Of Medicine
-
-
New York
-
New York, New York, Vereinigte Staaten, 10029
- Rekrutierung
- Mount Sinai Medical Center
-
-
Ohio
-
Columbus, Ohio, Vereinigte Staaten, 43235
- Rekrutierung
- The Boster Center for Multiple Sclerosis
-
Columbus, Ohio, Vereinigte Staaten, 43221
- Rekrutierung
- The Ohio State University Wexner Medical Center (OSUWMC)
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- Rekrutierung
- OMRF Multiple Sclerosis Center of Excellence
-
-
South Carolina
-
Greenville, South Carolina, Vereinigte Staaten, 29605
- Rekrutierung
- Premier Neurology
-
-
Tennessee
-
Cordova, Tennessee, Vereinigte Staaten, 38018
- Rekrutierung
- Neurology Clinic, P.C.
-
-
Texas
-
San Antonio, Texas, Vereinigte Staaten, 78258
- Rekrutierung
- Lone Star Neurology
-
Sherman, Texas, Vereinigte Staaten, 75092
- Rekrutierung
- Texas Institute for Neurological Disorders - Sherman
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- 18 to 60 years of age, inclusive, at the time of signing the informed consent.
- Participant must have a previous diagnosis of RRMS in accordance with 2024 McDonald criteria
- Participant must have a current diagnosis of SPMS in accordance with the clinical course criteria revised in 2013
- Participant must have documented evidence of disability progression independent of clinical relapse observed during the 24 months before screening. A written summary of the clinical evidence of disability progression must be discussed and aligned between the Investigator and the Sponsor's dedicated qualified person(s).
- Absence of clinical relapses for at least 24 months.
Exclusion Criteria:
- The patient has been diagnosed with primary progressive MS (PPMS) according to 2024 McDonald diagnostic criteria
- Immunologic disorder other than MS or any other conditions requiring corticosteroid therapy.
- History or current diagnosis of other neurological disorders that may mimic MS
- History or current diagnosis of progressive multifocal leukoencephalopathy
- Active, clinically significant viral, bacterial, or fungal infection
- History of any other significant active medical condition
- History of suicidal behavior within 6 months prior to Screening
- Any prior history of malignancy
- Patients on anticoagulation, or antiplatelet therapy
- Patients took strong/moderate CYP3A inhibitors or strong/moderate CYP3A inducers within 14 days
- Clinically significant laboratory abnormalities at Screening.
- Vaccination with live or live-attenuated virus vaccine within 1 month prior to Screening
- History of alcohol abuse or alcohol use disorder or other drug abuse within 12 months prior to screening.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Orelabrutinib Group
Orelabrutinib PO daily |
Orelabrutinib orally |
|
Placebo-Komparator: Placebo Group
Placebo PO daily |
Placebo orally |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Time to onset of confirmed disability progression (CDP) events, confirmed over at least 24 weeks
Zeitfenster: Up to approximately 120 weeks
|
Expanded disability status scale (EDSS) score increase ≥ 1.0 point from baseline when the baseline score is ≤ 5.0, or ≥ 0.5 points from baseline when the baseline score is > 5.0 |
Up to approximately 120 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
12 Week CDP
Zeitfenster: Up to approximately 120 weeks
|
Time to onset of CDP events on EDSS, confirmed over at least 12 weeks |
Up to approximately 120 weeks
|
|
T2 lesions on MRI
Zeitfenster: Up to approximately 120 weeks
|
The total number of new or enlarging T2 lesions on MRI scans of the brain |
Up to approximately 120 weeks
|
|
24-week CDP-9-hole Peg Test
Zeitfenster: Up to approximately 120 weeks
|
Time to onset of CDP events on 9-hole Peg Test (9HPT), defined as ≥ 20% increase on 9HPT from baseline, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
24-week CDP-T25FWT
Zeitfenster: Up to approximately 120 weeks
|
Time to onset of CDP events on Timed 25-Foot Walk Test (T25FWT), defined as ≥ 20% increase on T25FWT from baseline, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
24-week CDI
Zeitfenster: Up to approximately 120 weeks
|
Time to onset of confirmed disability improvement (CDI) events on EDSS, defined as ≥ 1.0-point decrease on the EDSS score from baseline when the baseline score is ≤ 5.0, or ≥ 0.5 points from baseline when the baseline score is > 5.0, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
24-week CDI-9HPT
Zeitfenster: Up to approximately 120 weeks
|
Time to onset of CDI events on 9HPT, defined as ≥ 20% decrease on the 9HPT score from baseline, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
24-week CDI-T25FWT
Zeitfenster: Up to approximately 120 weeks
|
Time to onset of CDI events on T25FWT, defined as ≥ 20% decrease on the T25FWT score from baseline, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
Symbol Digit Modalities Test
Zeitfenster: Up to approximately 120 weeks
|
The change in cognitive function as assessed by Symbol Digit Modalities Test (SDMT) from baseline to each scheduled visit |
Up to approximately 120 weeks
|
|
Annualized relapse rate
Zeitfenster: Up to approximately 120 weeks
|
Annualized relapse rate (ARR) during the study period assessed by protocol-defined adjudicated relapses |
Up to approximately 120 weeks
|
|
To evaluate the safety and tolerability of orelabrutinib
Zeitfenster: Up to approximately 120 weeks
|
Safety as assessed by the nature, severity, and incidence of adverse events (AEs) (graded according to National Cancer Institute-Common Terminology Criteria for AEs, NCI-CTCAE version 5.0); |
Up to approximately 120 weeks
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Nervensystems
- Pathologische Prozesse
- Chronische Erkrankung
- Krankheitsattribute
- Autoimmunerkrankungen
- Erkrankungen des Immunsystems
- Demyelinisierende Autoimmunerkrankungen, ZNS
- Autoimmunerkrankungen des Nervensystems
- Demyelinisierende Krankheiten
- Pathologische Zustände, Anzeichen und Symptome
- Multiple Sklerose
- Multiple Sklerose, chronisch progressiv
- Orelabrutinib
Andere Studien-ID-Nummern
- ZB020-03-002
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .